Recce Pharmaceuticals includes a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.
US based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and Lead Director of Heat Biologics, Inc. (NASDAQ: HTBX) – extensive experience in the international commercialisation of pharmaceutical technologies.
Five years as former Executive Director and extensive experience in marketing, business development and commercialisation of early-stage technologies with global potential.
Co-inventor and qualified medical scientist; specialisation in medical microbiology and regulatory affairs.
A quality control expert who has worked with leading pharmaceutical companies. He is bringing Recce’s research and development and manufacturing up to US FDA requirements.
US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (J&J Research). Dr Dunton has advanced a number of blockbuster antibiotics through regulatory review and commercialization at Fortune 500 companies including J&J and Roche.
Highly qualified in chemical engineering and microbiology with significant experience taking a new technology concept to pilot plant and full-scale to FDA standards and production internationally.
Experienced marketing specialist in the pharmaceutical and clinical trial sector with expertise in digital marketing campaigns and targeting key investors in the healthcare industry.
Alistair is a qualified lawyer and Principal of Automic Legal. Alistair has broad experience as a commercial litigator and Company Secretary to ASX Listed companies.
Justin is a qualified accountant and Partner of Pitcher Partners Sydney. Justin has broad experience covering all areas of accounting, taxation and assurance. Particularly, Justin’s areas of expertise are business services and outsourced accounting.
Leading spinal injury physician at Royal North Shore Hospital. Dr Bowers has a specialist interest in the treatment of complex and life-threatening antibiotic resistant infections, particularly among patients with severe spinal cord injuries.
Global infectious disease expert with over 30 years of research and industry experience, having served as former Head of Immunology at CSL Ltd in Melbourne. Chief Editor of textbook “Helicobacter pylori in the 21st Century” and has co-authored 92 manuscripts published in peer-reviewed journals. Professor Sutton currently leads the Mucosal Immunology Group at Murdoch Children’s Research Institute.
Receive news and information direct to your inbox.
ASX: